12:00 AM
 | 
Aug 20, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD52; T cell receptor (TCR)

Cancer

INDICATION: Lymphoma

Mouse studies suggest chimeric antigen receptor (CAR) T cells that lack CD52 and endogenous TCR could treat lymphoma. Endogenous TCR on CAR T cell therapies reduces cell survival in vivo and can cause graft-versus-host-disease (GvHD). In mice, human...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >